NIVOPOSTOP (GORTEC 2018‑01) Trial Overview
Aim & Context
The NIVOPOSTOP trial evaluated whether adding nivolumab (Opdivo) to standard postoperative chemoradiotherapy could improve outcomes in patients with locally advanced, high-risk squamous cell carcinoma of the head and neck (HNSCC). This patient group typically faces a high relapse risk (~40–50%) after surgery followed by chemoradiotherapy.
Study Design
Type: International, open-label, randomized Phase III study (GORTEC 2018‑01, NCT03576417) . Population: 680 patients, aged <75, performance status 0–1, high-risk features (e.g., extracapsular nodal extension, positive margins, multiple lymph nodes, perineural invasion) following complete surgical resection . Arms: Control: Standard chemoradiotherapy (CRT) — cisplatin‑RT (66 Gy + 3 cycles of cisplatin) . Experimental: Nivolumab lead-in dose → CRT plus nivolumab (360 mg Q3W for 3 cycles) → maintenance nivolumab (480 mg Q4W for 6 cycles) .
Key Efficacy Outcomes
Disease-Free Survival (DFS): Met the primary endpoint. At median follow‑up of 30.3 months, DFS was significantly improved with nivolumab: 3‑year DFS: 63.1% vs 52.5% (hazard ratio [HR] = 0.76; 95% CI, 0.60–0.98; p = 0.034) . Locoregional recurrences were reduced (13% with nivolumab vs 20% with CRT alone; HR 0.63) . Benefit observed regardless of PD‑L1 expression (including PD‑L1 negative patients) .
Overall Survival (OS)
OS data are not mature yet, but trends favor nivolumab: 3‑year OS: ~74.2% (nivolumab + CRT) vs ~67.8% (CRT alone) . Final OS analysis pending further events, expected in future years .
Safety & Tolerability
Early grade 3–4 adverse events (within first 100 days) were higher with nivolumab (13.1% vs 5.6%), including neutropenia and lymphocytopenia . No increase in treatment-related mortality (0.6% vs 0.7%) . Late toxicities beyond 9 months were rare and limited to grade 3 or below . Nivolumab did not delay or reduce compliance with chemoradiotherapy; immune-related toxicities (e.g., thyroid issues) were manageable .
Clinical Implications
First major advance in adjuvant therapy for high-risk, resected HNSCC in decades. DFS improvement suggests nivolumab + CRT may become a new standard of care for these patients . OS benefit promising, pending final analysis. Safety is acceptable and does not compromise treatment delivery.
